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Background: Inhaled endotoxin or lipopolysaccharide (LPS) is implicated in the
pathogenesis of pulmonary diseases. We investigated the inhalation effects of two
different doses of LPS in healthy human subjects.
Methods: Eighteen healthy non-atopic human subjects inhaled either 15 mg ðn ¼ 10Þ
or 50 mg ðn ¼ 8Þ Escherichia coli LPS in an open study. As control, each subject had
isotonic saline inhalation 1 week before (baseline) and after LPS inhalation. Data
collected included those of clinical parameter, induced sputum and peripheral blood
CD4+ and CD8+ T cells.
Results: Acute flu-like symptoms and pyrexia were significantly greater in the 50 mg
than 15 mg LPS group. Similarly, the increase in sputum and blood total cell and
neutrophil counts at 6 h following inhaled LPS were greater in the 50 mg group.
Myeloperoxidase, human neutrophil elastase and interleukin-8 in sputum sol, but not
blood, showed a trend towards greater increase following 50 mg LPS. All these
changes were resolved at one week. In the 50 mg dose group alone, there was a
reduction in the proportion of peripheral blood interferon (IFN)-g-producing CD4+
and CD8+ T cells at 6 h followed by an increase at 1 week after inhaled LPS.
Conclusions: The airway and systemic effects of inhaled LPS are dose-related and
predominantly neutrophilic. The changes in the proportions of circulating CD4+ and
CD8+ T cells suggests preferential recruitment of IFN-g-producing T cells into tissue
from inhaled 50mg LPS, followed by reappearance of these cells in blood 1 week later.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Inhaled bacterial endotoxin can cause lung inflam-
mation1–4 and is implicated in the pathogenesis of
pulmonary diseases such as organic dust lung
diseases,5,6 asthma,7,8 chronic obstructive pulmon-
ary disease9,10 and acute lung injury.11,12 Studies
using inhaled endotoxin or its pure derivative,
lipopolysaccharide (LPS) in human subjects have
shown that the nature of inflammation is predomi-
nantly neutrophilic1,3,4 and dose-related.2,13 The
latter supports the observation that chronic ex-
posures increase risk for lung injury.10,14,15 The
threshold for inducing clinical symptoms and lung
function changes in healthy human subjects is
probably between 30 and 40 mg of inhaled LPS.16
To further our understanding of endotoxin-in-
duced lung injury, we investigated1 The systemic
(clinical effects, airway and blood) effects of
inhaled LPS at single doses of 15 and 50 mg, in
healthy non-atopic human subjects, up to one
week, and2 whether there were any changes in
the peripheral blood interleukin (IL)-4- and inter-
feron (IFN)-g-producing CD4+ and CD8+ T cells
following inhaled LPS at these doses, using the
technique of intracellular flow cytometry.Visit 1 Visit 2 Visit 3
4 to 7 days 7 days
Saline challenge
(baseline)
LPS challenge Saline challenge
(one week post LPS)
Induced sputum and blood at 6 hours
clinical observations at 2 hourly *
* only performed at Visit 2 and 3
  self-reporting questions on symptoms were collected at Visit 3
Diagram A The study design depicting the order of
inhalation challenges.Methods
Subjects
Eighteen healthy human subjects were recruited
through local contacts. The inclusion criteria were
non-cigarette smokers for at least 6 months and if
previously smoked, did not exceed 5 pack years; no
physician-diagnosed respiratory disease; non-ato-
pic as defined by negative skin prick reactivity to
common aeroallergen, normal spirometry, and
methacholine PC20 of 416mg/ml. Urine cotinine
was measured to confirm the history of non-
cigarette smoking.
Study design
This was an open study where 10 subjects [mean
(range) age: 31 yr (26–39); five males; mean (95%
CI) FEV1: 97 (89–106)% predicted normal] inhaled
15 mg and eight subjects [age: 28 yr (21–35); five
males; FEV1: 104 (92–117)% predicted normal]
inhaled 50 mg LPS. After a screening visit to
examine eligibility, each subject attended three
visits, each separated by 1 week. At each visit,
induced sputum and blood were collected at 6 h
after inhaling either 0.9% isotonic saline (visit 1 and3) or LPS (visit 2) via a breath activated dosimeter
(Mefar MB3 dosimeter, Brescia, Italy). This time
point for collecting sputum and blood was chosen
based on the approximation to the onset of ‘flu-
like’ symptoms in healthy human subjects from our
preliminary studies of three subjects (data not
shown) and findings of neutrophilia at such time
point.2,17 Temperature, blood pressure, pulse and
respiratory rate were recorded prior to and every
two hourly (up to 8 h) after inhalation of LPS (visit
2) or saline (visit 3). Spirometry was measured
before LPS challenge, during sputum induction and
at 8 h after inhalation challenge. Each subject filled
in a self-reporting questionnaire on respiratory
symptoms and their severity (graded as mild,
moderate or severe) at visit 2. The order of
inhalation challenges was the same for all subjects
and not randomized (Diagram A). The rationale for
separating all challenges by 1 week was to avoid
conducting serial sputum induction at too close an
interval. This might be important because inhaled
hypertonic saline used for sputum induction can
itself cause airway neutrophilia.18,19 Such occur-
rence might confound the interpretation of sputum
results following inhaled LPS challenge. Sputum
cellular indices have been shown to be reproducible
for up to 1 week.20,21 The study protocol was
approved by local hospital ethics committee and
written informed consent was obtained from all
subjects.Inhalation of LPS
Each LPS solution was freshly made up prior to each
inhalation using the powder formulation of Escher-
ichia coli serotype 026:B6 (Sigma, Poole, UK)
diluted with 0.9% pyogen-free normal saline, and
delivered via dosimeter (Mefar MB3 dosimeter,
Brescia, Italy) according to the standard protocol.22
Based on a 10 ml volume delivered per inhalation,
five inhalation of a 0.25mg/ml LPS solution would
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LPS solution would deliver 50 ml LPS into the airway.Sputum induction and processing
Hypertonic saline at concentrations of 3%, 4% and
5% was inhaled via an ultrasonic nebuliser (DeVilbiss
Ultra-Neb 2000, Heston, Wollaston, UK) sequen-
tially for 7min each.23 After each 7-min period,
subjects were asked to rinse and gargle mouth and
throat to get rid of saliva and other debris before
coughing into a sterile container. Monitoring of FEV1
during each inhalation was performed for safety
reason. We had intentionally omitted pre-treat-
ment with short-acting inhaled b2-agonist in order
to avoid any possible modifying effect on LPS-
induced airway inflammation.
The sputum was selected from saliva and
processed within 2 h.21 Sputum was first homoge-
nised by adding four volumes of freshly made 0.1%
dithiothreitol (DTT) (Sputolysin, Calbiochem Ltd,
Nottingham, UK) that was then added equal volume
of Modified HBSS (without Ca2+/Mg2+) (Sigma,
Poole, UK). The cell suspension was filtered through
a 48 mm nylon gauze (BBSH Thompson, Scarbor-
ough, Ontario, Canada) and the filtrate centrifugedTable 1 Symptoms reported in the (A) 15 mg and (B) 50
Subjects Muscle ache Headache
(A)
1
2 + +
3
4 + +
5
6 +++ +++
7 ++ +
8
9 ++ +++
10 +
Subjects Headache Chest tightness
(B)
1 ++ +
2 +++ ++
3 ++
4 + +
5 +++ +
6 ++
7 +++ ++
8 ++ ++
Symptoms are in descending order of frequency from left to righ
+ mild, ++ moderate, +++ severe.
This subject also complained of mouth ulcers that lasted forat 3000 rpm for 4min at room temperature. The
supernatant (sputum sol) was aspirated and stored
at 70 1C for future assay while the cell pellet was
re-suspended with HBSS. Total cell count and cell
viability were determined using trypan blue exclu-
sion. The cell suspension was finally adjusted to
0:5 106 cells=ml and placed into cups of Shandon
III cytocentrifuge (Shandon, Inc. Pittsburgh, PA,
USA) to make cytoslides. After air-dried, cytoslides
were stained with Wright’s Giemsa for differential
cell count on at least 400 non-squamous cells.
These cytoslides were counted by two independent
observers.Myeloperoxidase (MPO), human neutrophil
elastase (HNE) and IL-8 in sputum sol and
serum
MPO and IL-8 levels was measured by radioimmu-
noassay (Pharmacia & Upjohn Ltd, Milton Keynes,
UK) and colorimetric enzyme immunoassay (R&D
Systems, Abingdon, UK), respectively, according to
standard protocols. Their sensitivity limits were
8 ng/ml and 31.2 pg/ml, respectively. HNE activity
was estimated based on a colorimetric reaction
assay where the rate at which HNE cleaved amg LPS group.
Chills Chest tightness Cough
+
++
+
++ +++
+
+ + ++
++ +
Muscle ache Chills Cough
+++ +
++ +
++ +
++ ++ +
+ +
++ +++ +++
t columns.
5 days.
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Figure 1 Temperature change following inhaled (A) 15 mg
and (B) 50 mg LPS. Symbols and bars represent mean and
standard error. ***Po0.001, **Po0.01, *Po0.05 compared
to inhaled saline.
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was measured. Each sample was assayed in singlet
and into each well of a 96-well microtitre plate,
pipetted in the following order: 100 ml of substrate
buffer (7.88 g Tris HCL, 8.77 g NaCl; 400ml deio-
nised water; adjusted to pH 8.6), 20 ml of study
sample, 60 ml of deionised water and neutrophil
elastase substrate (20 ml methoxy succinyl-ala-ala-
pro-val p-nitroanilide in 25% DMSO). The plate was
then immediately placed in a kinetic plate reader
(Spectromax 250 spectrophotometer) and shaken
for 5 s and read at 405 nm every minute over a
period of 30min at 30 1C. The SoftMax Pro software
plotted the progress of each reaction and deter-
mined Vmax between minimum and maximum
optical densities of 0–3 OD units. Individual plots
for each sample were scrutinised to see whether
the reaction had entered the linear phase and if
necessary, sample was further diluted and re-
assayed. Quality control samples, prepared from
samples of disrupted blood neutrophils suspended
in hexadecyltrimethylammonium bromide (HTAB)
(Sigma, Poole, UK), were placed at the beginning
and the end of the sample sequence for each assay.
Vmax was used to indicate HNE activity, presented
as the final result in millioptical density units per
minute (mOD/min). The method has the sensitivity
limits of 0.1mOD/min.
Peripheral blood mononuclear cells (PBMC)
Fifty millilitre venous blood was collected from
each subject in a syringe containing 1% sodium
citrate and processed within 2 h. After dilution 1:4
with Hanks balanced salt solution (HBSS) (Life-
Technology, Paisley, UK), PBMC were isolated by
Ficoll-Hypaque density gradient centrifugation
(Pharmacia, Uppsala, Sweden) at 800g for 20min
at 18 1C and then washed with cold HBSS at 600g for
10min at 4 1C. Viable cell numbers were deter-
mined by trypan blue exclusion then washed twice
with HBSS at 200g for 10min at 4 1C and re-
suspended at 1 107=ml in PBS/ 2% foetal calf
serum (FCS) (Harlon-Seralab, Loughborough, UK).
Isolation and purification of CD4+ and CD8+ T
cells
CD4+ and CD8+ T cells were isolated by positive
selection using anti-CD4 and anti-CD8 magnetic
beads and Detach-a-bead antibody (Dynal, Wirral,
UK) and re-suspended at 1 106 cells=ml in culture
medium (RPMI medium, supplemented with 5%
human albumin serum, 100 IU/ml penicillin/strep-
tomycin, and 2mmol/l L-glutamine). An aliquot ofCD4+ and CD8+ T cells were analysed on a
FACScalibur to check purity (Becton Dickinson,
Oxford, UK) which was 499% for both CD3+CD4+
and CD3+CD8+ cells.Cell culture and intracellular cytokine
staining
CD4+ and CD8+ T cells at a density of 1 106=ml
were plated out in duplicate into flat-bottom 96-
well microtitre plates and stimulated with immo-
bilised anti-CD3 (1:100 dilution) and anti-CD28
(1:1000 dilution) (Pharmingen/Becton Dickinson,
Oxford, UK), for 4 days. After 4 days of culture,
cells were re-stimulated with PMA (10 ng/ml) and
ionomycin (400 ng/ml) (Sigma, Poole, UK) overnight
and during the final 6 h, incubated with protein
synthesis inhibitor, brefeldin-A (5 mg/ml) (Sigma,
Poole, UK). Cell cultures were then gently re-
suspended and transferred to FACS tubes and spun
down at 200g for 10min. Supernatants were
discarded and the cells washed in 2ml of PBS/
0.1% BSA (Sigma, Poole, UK) and centrifuged at
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fixed for 30min at room temperature in the dark
with 1ml of hypertonic 4% formaldehyde. Cells
were centrifuged at 200g for 5min and the fixative
removed. Fixed cells were then permeabilised by
the addition of 2ml 0.5% saponin solution (Sigma,
Poole, UK) for 30min at room temperature in the
dark. These cells were spun down at 200g for 5min,
and then stained for intracellular cytokines with
anti-IL-4-PE and anti-IFN-g-FITC (Becton Dickinson,
Oxford, UK) for 30min at room temperature in the
dark. Cells were washed with saponin solution and
fixed with 1% paraformaldehyde, ready for flow
cytometric analysis (FACScalibur).Data analysis
All results were expressed as mean and standard
error. Significance of difference from baseline, 6 h
and 1 week post LPS inhalation was studied using
repeated measures analysis of variance (ANOVA).
Where significant variation was found, Dunnett’s
multiple comparison was used to investigate the
significance of change between time points. Sincebaseline 6 hours
post LPS
1 week
baseline 6 hours
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1 week
0
10
20
30 15 µg LPS
15 µg LPS ***
**
sp
ut
um
 to
ta
l c
el
l c
ou
nt
(x1
0-6
 
ce
lls
/ m
l)
(x1
0-6
 
ce
lls
/ m
l)
0
10
20
30
sp
ut
um
 m
ac
ro
ph
ag
e 
co
un
t
(A)
(C)
Figure 2 Induced sputum total cell and differential counts at
and 50 mg ðn ¼ 6Þ. ***Po0.001, **Po0.01 compared to inhaled
standard error.the distribution approximates normality, signifi-
cance of variance in the airway and systemic
effects between subjects receiving 15 and 50 mg
LPS was analysed using unpaired t tests. All
statistical analysis and graphic representation of
data were carried out on the GraphPad PrismTM
graphic and statistical package (PC Windowss
version). For all statistical tests, Po0.05 was
considered significant.Results
Most subjects experienced flu-like symptoms fol-
lowing LPS inhalation, the commonest of which
were headache, chills and muscle ache. These
symptoms were acute occurring as early as 2 h
and mostly resolved by 24 h. One in the 15 mg
group however complained of mouth ulcers that
lasted for 5 days. In general, the symptoms were
more common and severe in the 50 mg LPS group
(Table 1). Temperature was significantly higher in
the 50 mg LPS, compared to the 15 mg LPS, beginning
from the 4th h onwards (Fig. 1). Spirometric data,baseline 6 hours
post LPS
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baseline 6 hours
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baseline, 6 h and 1 week after inhaled 15 mg LPS ðn ¼ 10Þ
isotonic saline (baseline visit 1). Bars represent mean and
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Figure 3 Peripheral blood total leukocyte and differential counts at baseline, 6 h and 1 week after inhaled 15 mg LPS
ðn ¼ 10Þ and 50 mg ðn ¼ 8Þ. **Po0.01, *Po0.05 compared to inhaled isotonic saline (baseline visit 1). Bars represent
mean and standard error.
L.C. Loh et al.524blood pressure, pulse and respiratory rate, were
not significantly altered at either dose (data not
shown).
Total cell and neutrophil counts in induced
sputum were significantly increased at 6 h following
LPS inhalation, compared to inhaled saline (base-
line visit 1) with a greater trend towards increase in
the 50 mg, compared with the 15 mg dose [mean
increase (SEM): 22.36 (3.09) vs. 15.17 ð4:17Þ 
106 cells=ml of total cells; P ¼ 0:25; 19.71 (2.54)
vs. 13.82 ð3:80Þ  106 cells=ml of neutrophils;
P ¼ 0:29]. By 1 week, sputum total cell and
neutrophil counts had returned to baseline in
both groups. The levels of sputum macrophages,
lymphocytes and eosinophils were not signi-
ficantly altered by LPS inhalation at either dose
(Fig. 2).
In peripheral blood, total white cell and neu-
trophil counts were also significantly elevated at
6 h following LPS inhalation, compared to inhaled
saline (baseline visit 1). The increase was signifi-
cantly greater with 50 mg than with 15 mg LPS [meanincrease (SEM): 7.59 (0.91) vs. 4.58 ð0:82Þ 
106 cells=ml of blood neutrophils; P ¼ 0:007]. By 1
week, these blood changes had returned to base-
line in both groups. There was a small but
significant reduction of blood monocytes at 6 h
following 50 mg, but not 15 mg inhaled LPS, while
lymphocytes and eosinophils remained unaltered
(Fig. 3).
Overall, inhalation of LPS increased sputum sol
MPO, HNE and IL-8 at 6 h, compared with inhaled
saline (baseline visit 1). The increase of MPO and
HNE was statistically significant at 15 mg LP, while
the increase in IL-8 was statistically significantly at
50 mg LPS. By 1 week, their levels were comparable
to those at baseline (Fig. 4). Except for a minimal
trend towards increase in serum MPO following
inhaled LPS compared to inhaled saline (baseline
visit 1), the HNE activity and IL-8 levels (except
two) in all serum samples were below quantifiable
levels [data not shown].
At 50 mg dose alone, there was a reduction in the
proportion of peripheral blood IFN-g-producing
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Figure 4 Effects of inhaled 15 mg LPS and 50 mg on in
sputum sol sputum sol (A) myeloperoxidase (MPO), (B)
human neutrophil elastase (HNE), and (C) IL-8 at base-
line, 6 h and 1 week after inhalation. Bars represent
mean and standard error. **Po0.01, *Po 0.05 compared
to inhaled isotonic saline (baseline visit 1).
Inhaled endotoxin in healthy human subjects 525CD4+ [mean (SEM) %: 3.59 (0.67) vs. 1.60 (0.22)] and
CD8+ T cells [5.99 (0.57) vs. 2.84 (0.65)] at 6 h
followed by an increase at 1 week after inhaled LPS
[CD4+: 6.41 (1.03); CD8+: 10.86 (2.46)]. The
increase at 1 week later was statistically significant
when compared with baseline (in CD4+ cells) and
6 h following inhaled LPS (in CD4+ and CD8+ cells).
Otherwise, there was no significant difference inthe proportion of circulating IL-4-producing CD4+ or
CD8+ cells at either dose of LPS (Figs. 5 and 6).Discussion
We have shown that the systemic effects of inhaled
LPS were greater at 50 mg than at 15 mg dose in
healthy human subjects. The inflammatory nature
was predominantly neutrophilic and more promi-
nent in airway than in blood. It was transient in that
they were not present after 1 week. Most un-
expected finding was a reduction in the proportion
of circulating IFN-g-producing CD4+ and CD8+ T
cells at 6 h after inhaled LPS, followed by a
significant increase in these cells 1 week later.
This pattern of change was only observed at
50 mg dose.
The pyrexia and acute ‘flu-like’ symptoms re-
ported in our findings are similar to those from
other studies,2,4 but perhaps more prominent.
Although a 30–40 mg dose is probably the threshold
for inducing symptoms and lung function changes in
healthy subjects,16 we showed that most subjects
receiving 15 mg dose were symptomatic. Two sub-
jects from the group graded the symptoms as
severe and one of them had mouth ulcers that
lasted for 5 days. Despite the symptoms, we did not
report any impairment of FEV1 or FVC in both
groups. Others have shown both a reduction4 and
normality2,3 of FEV1 and FVC in healthy subjects
challenged with inhaled LPS. Kline et al.24 recently
showed that the provocation concentration of
inhaled LPS to induce a 20% fall in FEV1, varied
considerably in 72 healthy subjects. In those
who were sensitive to the effects of inhaled
LPS, their peripheral blood monocytes elaborated
less IL-6 and IL-8, suggesting that there are
inherent differences in individual responsiveness
to inhaled LPS.
Like previously reported,1,3,4 a single inhaled LPS
in healthy subjects evokes a predominantly neu-
trophilic response. Michel et al.2 showed a dose–r-
esponse relationship between airway and blood
inflammatory responses based on weekly bronchial
challenges with ascending doses of inhaled LPS in
healthy subjects. Our findings add to the evidence
of dose-related effects and further extend our
understanding on this in showing that the effects of
single inhaled LPS at these studied doses is
transient in healthy subjects, as evidenced by the
absence of airway neutrophilia after 1 week of LPS
challenge. This is important because activated
neutrophils have been shown to perpetuate further
neutrophil recruitment, by a positive autocrine
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Figure 5 The effects of inhaled 15 and 50 mg LPS on peripheral blood (A) IFN-g- and (B) IL-4-producing CD4+ and CD8+ T
cells. *Po 0.05, **Po0.01. Bars represent mean and standard error.
L.C. Loh et al.526feedback loop, independent of initiating stimulus
of the inflammatory response in disease state such
as bronchiectasis.25 This process is possibly
mediated by IL-8, a potent neutrophil chemoat-
tractant, the degree of which is both amplified and
sustained in the presence of IL-1b and TNF-a.26,27
This view may partly explain the difficulty in
correlating microbiologic findings and inflammation
during the clinical episodes of infection.28
It is also noteworthy that although the neutro-
phil-related mediators and IL-8 showed towards a
greater increasing trend following inhaled 50 mg
compared to 15 mg LPS dose, it was not consistent.
This lack of parallel increase with neutrophilia
suggests that the LPS-induced response at these
studied doses is primarily one of cell recruitment,
not enhanced activation/degranulation. This con-
cept is also supported by others in their findings of
normal2 or reduced4 ratios of neutrophil mediators
over neutrophil number.
It is well established that bacterial endotoxin
induces a Type 1 T cell response in human sub-
jects.29,30 LPS is capable of stimulating human Tcells directly but this process requires cell-to-cell
contact with accessory cells such as monocytes and
is MHC unrestricted.31 Our novel observation of a
trend towards reduction in the proportion of blood
IFN-g-producing CD4+ and CD8+ T cells 6 h after
50 mg inhaled LPS is best explained by preferential
recruitment of these circulating cells to the local
sites of inflammation or lymphoid tissue. The
observation of significant increase in the proportion
of blood IFN-g-producing CD4+ and CD8+ T cells
after 1 week was unexpected, and may be
explained as a ‘rebound’ phenomenon in that the
earlier recruited IFN-g-producing T cells re-emerge
in peripheral circulation. In animals, LPS injection
is shown to cause an accumulation of IFN-g-
producing T cells in pleural cavity that resolves
after 96 h,32 suggesting that the recruitment
process is temporary after a single challenge.
These T cells may be confined to memory cells
alone.33 Further research is required to define the
phenotypes of these T cells at 1 week after inhaled
LPS and to study whether 50 mg dose represents a
threshold level of enrolling these T cells.
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Figure 6 A representative FACS dot plot from a subject showing a reduction in the proportion of IFN-g-producing CD4+
and CD8+ T cells at 6 h (visit 2) followed by an increase at 1 week after inhaled 50 mg LPS (visit 3).
Inhaled endotoxin in healthy human subjects 527
ARTICLE IN PRESS
L.C. Loh et al.528Acknowledgements
The authors wish to thank Dr. Paul Linacre and Ms.
Jo Thompson from GlaxoWellcome R&D for the
technical support in the measurement of sputum
sol and serum MPO, HNE and IL-8.References
1. Sandstrom T, Bjermer L, Rylander R. Lipopolysaccharide
(LPS) inhalation in healthy subjects increases neutrophils,
lymphocytes and fibronectin levels in bronchoalveolar
lavage fluid. Eur Respir J 1992;5:992–6.
2. Michel O, Nagy AM, Schroeven M, et al. Dose–response
relationship to inhaled endotoxin in normal subjects. Am J
Respir Crit Care Med 1997;156:1157–64.
3. Nightingale JA, Rogers DF, Hart LA, et al. Effect of inhaled
endotoxin on induced sputum in normal, atopic, and atopic
asthmatic subjects. Thorax 1998;53:563–71.
4. Thorn J, Rylander R. Inflammatory response after inhalation
of bacterial endotoxin assessed by the induced sputum
technique. Thorax 1998;53:1047–52.
5. Rylander R. Bacteria as etiological agents in byssinosis and
other lung disease. Eur J Respir Dis 1982;63:34–46.
6. Thelin A, Tegler O, Rylander R. Lung reactions during poultry
handling related to dust and bacterial endotoxin levels. Eur
J Respir Dis 1984;65:266–71.
7. Michel O, Kips J, Duchateau J, et al. Severity of asthma is
related to endotoxin in house dust. Am J Respir Crit Care
Med 1996;154:1641–6.
8. Rizzo MC, Naspitz CK, Fernandez-Caldas E, Lockey RF,
Mimica I, Sole D. Endotoxin exposure and symptoms in
asthmatic children. Paediatr Allergy Immunol 1997;8:121–6.
9. Smid T, Heederik D, Houba R, Quanjer PH. Dust- and
endotoxin-related acute lung function changes and work-
related symptoms in workers in the animal feed industry. Am
J Ind Med 1994;25:877–88.
10. Schwartz DA. Grain dust, endotoxin, and airflow obstruc-
tion. Chest 1996;109:57S–63S.
11. Chignard M, Balloy V. Neutrophil recruitment and increased
permeability during acute lung injury induced by lipopoly-
saccharide. Am J Physiol Lung Cell Mol Physiol 2000;279:
L1083–90.
12. Kinoshita M, Mochizuki H, Ono S. Pulmonary neutrophil
accumulation following human endotoxemia. Chest 1999;
116:1709–15.
13. Jagielo PJ, Thorne PS, Watt JL, Frees KL, Quinn TJ, Schwartz
DA. Grain dust and endotoxin inhalation challenges produce
similar inflammatory responses in normal subjects. Chest
1996;110:263–70.
14. Castellan RM, Olenchock SA, Kinsley KB, Hankinson JL.
Inhaled endotoxin and decreased spirometric values. An
exposure-response relation for cotton dust. N Engl J Med
1987;317:605–10.
15. Rylander R, Bake B, Fischer JJ, Helander IM. Pulmonary
function and symptoms after inhalation of endotoxin. Am
Rev Respir Dis 1989;140:981–6.
16. Thorn J. The inflammatory response in humans after
inhalation of bacterial endotoxin: a review. Inflamm Res
2001;50:254–61.17. Alexis N, Eldridge M, Reed W, Bromberg P, Peden DB. CD14-
dependent airway neutrophil response to inhaled LPS: role
of atopy. J Allergy Clin Immunol 2001;107:31–5.
18. Nightingale JA, Rogers DF, Barnes PJ. Effect of repeated
sputum induction on cell counts in normal volunteers [see
comments]. Thorax 1998;53:87–90.
19. Holz O, Richter K, Jorres RA, Speckin P, Mucke M, Magnussen
H. Changes in sputum composition between two inductions
performed on consecutive days. Thorax 1998;53:83–6.
20. Spanevello A, Migliori GB, Sharara A, Ballardini L, Bridge P,
Pisati P, Neri M, Ind PW. Induced sputum to assess airway
inflammation: a study of reproducibility. Clin Exp Allergy
1997;27:1138–44.
21. Pizzichini E, Pizzichini MMM, Efthimiadis A, et al. Indices of
airway inflammation in induced sputum: reproducibility and
validity of cell and fluid-phase measurements. Am J Respir
Crit Care Med 1996;154:308–17.
22. Ward RJ, Reid DW, Walters EH. Variation in nebulizer output
and weight output from Mefar dosimeter: implications for
multicentre studies. Eur Respir J 1997;10:2436–7.
23. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced
sputum cell counts to investigate airway inflammation.
Thorax 1992;47:25–9.
24. Kline JN, Cowden JD, Hunninghake GW, et al. Variable
airway responsiveness to inhaled lipopolysaccharide. Am J
Respir Crit Care Med 1999;160:297–303.
25. Pang G, Ortega M, Zighang R, Reeves G, Clancy R. Autocrine
modulation of IL-8 production by sputum neutrophils in
chronic bronchial sepsis. Am J Respir Crit Care Med 1997;
155:726–31.
26. Fujishima S, Hoffman AR, Vu T, et al. Regulation of
neutrophil interleukin 8 gene expression and protein
secretion by LPS, TNF-alpha, and IL-1 beta. J Cell Physiol
1993;154:478–85.
27. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G.
Interleukin 10 (IL-10) inhibits the release of proinflammatory
cytokines from human polymorphonuclear leukocytes.
Evidence for an autocrine role of tumor necrosis
factor and IL-1 beta in mediating the production of IL-8
triggered by lipopolysaccharide. J Exp Med 1993;178:
2207–11.
28. Butt HL, Clancy RL, Cripps AW, Murree-Allen K, Saunders NA,
Sutherland DC, Hensley MJ. Bacterial colonisation of the
respiratory tract in chronic bronchitis. Aust NZ J Med
1990;20:35–8.
29. Le J, Lin JX, Henriksen-DeStefano D, Vilcek J. Bacterial
lipopolysaccharide-induced interferon-gamma production:
roles of interleukin 1 and interleukin 2. J Immunol 1986;
136:4525–30.
30. Gereda JE, Leung DY, Thatayatikom A, et al. Relation
between house-dust endotoxin exposure, type 1 T-cell
development, and allergen sensitisation in infants at high
risk of asthma. Lancet 2000;355:1680–3.
31. Mattern T, Flad HD, Brade L, Rietschel ET, Ulmer AJ.
Stimulation of human T lymphocytes by LPS is MHC unrest-
ricted, but strongly dependent on B7 interactions. J
Immunol 1998;160:3412–8.
32. Penido C, Castro-Faria-Neto HC, Larangeira AP, et al. The
role of gammadelta T lymphocytes in lipopolysaccharide-
induced eosinophil accumulation into the mouse pleural
cavity. J Immunol 1997;159:853–60.
33. Tough DF, Sun S, Sprent J. T cell stimulation in vivo by
lipopolysaccharide (LPS). J Exp Med 1997;185:2089–94.
